Ricky Goldwasser
Stock Analyst at Morgan Stanley
(3.36)
# 1,006
Out of 4,732 analysts
245
Total ratings
63.58%
Success rate
9.39%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LH Labcorp Holdings | Maintains: Overweight | $260 → $270 | $238.56 | +13.18% | 15 | Dec 17, 2024 | |
| ACCD Accolade | Maintains: Equal-Weight | $6 → $5 | $6.89 | -27.43% | 17 | Dec 17, 2024 | |
| DOCS Doximity | Upgrades: Equal-Weight | $33 → $53 | $53.72 | -1.34% | 9 | Nov 14, 2024 | |
| UNH UnitedHealth Group | Maintains: Overweight | $615 → $610 | $509.76 | +19.66% | 15 | Oct 16, 2024 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $7.99 | +25.16% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $4.57 | +20.35% | 9 | Nov 10, 2023 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $220 → $205 | $163.50 | +25.38% | 19 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $15.90 | -52.83% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $14.58 | -17.70% | 8 | Aug 30, 2023 | |
| CNC Centene | Downgrades: Equal-Weight | $94 → $73 | $62.25 | +17.27% | 10 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $145 | $151.20 | -4.10% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $286.21 | +27.53% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $592.57 | -29.12% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $9.55 | +1,156.54% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $282.63 | +119.37% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $385.29 | +29.77% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $52.62 | +135.65% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $283.99 | +11.98% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $126.27 | -44.56% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $43 → $39 | $12.52 | +211.50% | 15 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $197.36 | -1.20% | 6 | Oct 21, 2020 |
Labcorp Holdings
Dec 17, 2024
Maintains: Overweight
Price Target: $260 → $270
Current: $238.56
Upside: +13.18%
Accolade
Dec 17, 2024
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $6.89
Upside: -27.43%
Doximity
Nov 14, 2024
Upgrades: Equal-Weight
Price Target: $33 → $53
Current: $53.72
Upside: -1.34%
UnitedHealth Group
Oct 16, 2024
Maintains: Overweight
Price Target: $615 → $610
Current: $509.76
Upside: +19.66%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $7.99
Upside: +25.16%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $4.57
Upside: +20.35%
Charles River Laboratories International
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $220 → $205
Current: $163.50
Upside: +25.38%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $15.90
Upside: -52.83%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $14.58
Upside: -17.70%
Centene
Aug 30, 2023
Downgrades: Equal-Weight
Price Target: $94 → $73
Current: $62.25
Upside: +17.27%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $151.20
Upside: -4.10%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $286.21
Upside: +27.53%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $592.57
Upside: -29.12%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $9.55
Upside: +1,156.54%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $282.63
Upside: +119.37%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $385.29
Upside: +29.77%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $52.62
Upside: +135.65%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $283.99
Upside: +11.98%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $126.27
Upside: -44.56%
Jul 6, 2022
Maintains: Underweight
Price Target: $43 → $39
Current: $12.52
Upside: +211.50%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $197.36
Upside: -1.20%